Its time for Indian pharma companies to look beyond the U.S. market as the Trump administration has threatened to impose 25% tariff on pharmaceutical imports. This move would disrupt India’s ...

Mankind Pharma, India’s fourth largest drugmaker by domestic sales, is setting its sights on anti-obesity drugs like Semaglutide, better known by brand names Ozempic and Wegovy, which goes off ...

Shares of Teva Pharma marginally down 1% in early morning trading, while Alvotech's saw a 5% increase. Alvotech is in charge of development and manufacturing of Selarsdi, while Teva holds the ...

Publicly available export data suggest other pharma companies manufacture similar products, and drugs with different branding are widely available across West Africa. These manufacturers are ...

Feb 19 (Reuters) - U.S. President Donald Trump will meet on Thursday with chief executives from major drugmakers, a White House official confirmed to Reuters on Wednesday, as the industry tries to ...

The HHS announced that 5,200 staff from the FDA, NIH and CDC were at risk of losing their job on 14 February. Image credit: Shutterstock / Tada Images. Figures from across the pharmaceutical and ...

Dr. Reddy’s Laboratories fell 5.8% to Rs 1,128.90, while Zydus Lifesciences dropped 4.8%. Sun Pharma, India's largest drugmaker, declined by 3.2% to Rs 1,647.35, becoming the top loser on the BSE ...

Then came the threats of tariffs that the Indian pharma sector could face in the United States. How turbulent could the after-effects be of the possible tariffs? “The key strength of Indian ...

US tariffs on pharmaceutical imports will affect India’s pharma sector, a leader in affordable generics. Analyst Vishal Manchanda highlights risks to Indian firms like Sun Pharma and Cipla due to ...

Ilira Ndreu and Almir Zeqo take a selfie inside of a 100-foot spin sock on display at the 33rd Annual Kite Festival in Northeast Miami-Dade on Saturday, Feb. 15, 2025. Photo by Matias J.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...